Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
World Journal of Emergency Surgery
Published in: World Journal of Emergency Surgery 1/2016

Open Access 01-12-2016 | Review

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)

Authors: Massimo Sartelli, Dieter G. Weber, Etienne Ruppé, Matteo Bassetti, Brian J. Wright, Luca Ansaloni, Fausto Catena, Federico Coccolini, Fikri M. Abu-Zidan, Raul Coimbra, Ernest E. Moore, Frederick A. Moore, Ronald V. Maier, Jan J. De Waele, Andrew W. Kirkpatrick, Ewen A. Griffiths, Christian Eckmann, Adrian J. Brink, John E. Mazuski, Addison K. May, Rob G. Sawyer, Dominik Mertz, Philippe Montravers, Anand Kumar, Jason A. Roberts, Jean-Louis Vincent, Richard R. Watkins, Warren Lowman, Brad Spellberg, Iain J. Abbott, Abdulrashid Kayode Adesunkanmi, Sara Al-Dahir, Majdi N. Al-Hasan, Ferdinando Agresta, Asma A. Althani, Shamshul Ansari, Rashid Ansumana, Goran Augustin, Miklosh Bala, Zsolt J. Balogh, Oussama Baraket, Aneel Bhangu, Marcelo A. Beltrán, Michael Bernhard, Walter L. Biffl, Marja A. Boermeester, Stephen M. Brecher, Jill R. Cherry-Bukowiec, Otmar R. Buyne, Miguel A. Cainzos, Kelly A. Cairns, Adrian Camacho-Ortiz, Sujith J. Chandy, Asri Che Jusoh, Alain Chichom-Mefire, Caroline Colijn, Francesco Corcione, Yunfeng Cui, Daniel Curcio, Samir Delibegovic, Zaza Demetrashvili, Belinda De Simone, Sameer Dhingra, José J. Diaz, Isidoro Di Carlo, Angel Dillip, Salomone Di Saverio, Michael P. Doyle, Gereltuya Dorj, Agron Dogjani, Hervé Dupont, Soumitra R. Eachempati, Mushira Abdulaziz Enani, Valery N. Egiev, Mutasim M. Elmangory, Paula Ferrada, Joseph R. Fitchett, Gustavo P. Fraga, Nathalie Guessennd, Helen Giamarellou, Wagih Ghnnam, George Gkiokas, Staphanie R. Goldberg, Carlos Augusto Gomes, Harumi Gomi, Manuel Guzmán-Blanco, Mainul Haque, Sonja Hansen, Andreas Hecker, Wolfgang R. Heizmann, Torsten Herzog, Adrien Montcho Hodonou, Suk-Kyung Hong, Reinhold Kafka-Ritsch, Lewis J. Kaplan, Garima Kapoor, Aleksandar Karamarkovic, Martin G. Kees, Jakub Kenig, Ronald Kiguba, Peter K. Kim, Yoram Kluger, Vladimir Khokha, Kaoru Koike, Kenneth Y. Y. Kok, Victory Kong, Matthew C. Knox, Kenji Inaba, Arda Isik, Katia Iskandar, Rao R. Ivatury, Maurizio Labbate, Francesco M. Labricciosa, Pierre-François Laterre, Rifat Latifi, Jae Gil Lee, Young Ran Lee, Marc Leone, Ari Leppaniemi, Yousheng Li, Stephen Y. Liang, Tonny Loho, Marc Maegele, Sydney Malama, Hany E. Marei, Ignacio Martin-Loeches, Sanjay Marwah, Amos Massele, Michael McFarlane, Renato Bessa Melo, Ionut Negoi, David P. Nicolau, Carl Erik Nord, Richard Ofori-Asenso, AbdelKarim H. Omari, Carlos A. Ordonez, Mouaqit Ouadii, Gerson Alves Pereira Júnior, Diego Piazza, Guntars Pupelis, Timothy Miles Rawson, Miran Rems, Sandro Rizoli, Claudio Rocha, Boris Sakakhushev, Miguel Sanchez-Garcia, Norio Sato, Helmut A. Segovia Lohse, Gabriele Sganga, Boonying Siribumrungwong, Vishal G. Shelat, Kjetil Soreide, Rodolfo Soto, Peep Talving, Jonathan V. Tilsed, Jean-Francois Timsit, Gabriel Trueba, Ngo Tat Trung, Jan Ulrych, Harry van Goor, Andras Vereczkei, Ravinder S. Vohra, Imtiaz Wani, Waldemar Uhl, Yonghong Xiao, Kuo-Ching Yuan, Sanoop K. Zachariah, Jean-Ralph Zahar, Tanya L. Zakrison, Antonio Corcione, Rita M. Melotti, Claudio Viscoli, Perluigi Viale

Published in: World Journal of Emergency Surgery | Issue 1/2016

Login to get access

Abstract

Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients.
The cornerstones in the management of complicated IAIs are timely effective source control with appropriate antimicrobial therapy. Empiric antimicrobial therapy is important in the management of intra-abdominal infections and must be broad enough to cover all likely organisms because inappropriate initial antimicrobial therapy is associated with poor patient outcomes and the development of bacterial resistance.
The overuse of antimicrobials is widely accepted as a major driver of some emerging infections (such as C. difficile), the selection of resistant pathogens in individual patients, and for the continued development of antimicrobial resistance globally. The growing emergence of multi-drug resistant organisms and the limited development of new agents available to counteract them have caused an impending crisis with alarming implications, especially with regards to Gram-negative bacteria.
An international task force from 79 different countries has joined this project by sharing a document on the rational use of antimicrobials for patients with IAIs. The project has been termed AGORA (Antimicrobials: A Global Alliance for Optimizing their Rational Use in Intra-Abdominal Infections). The authors hope that AGORA, involving many of the world's leading experts, can actively raise awareness in health workers and can improve prescribing behavior in treating IAIs.
Appendix
Available only for authorised users
Literature
1.
Dellit TH, Owens RC, McGowan Jr JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America. Society for Healthcare Epidemiology of America Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77.PubMedCrossRef
2.
Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197:1079–81.PubMedCrossRef
3.
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12.PubMedCrossRef
4.
5.
Deege MP, Paterson DL. Reducing the development of antibiotic resistance in critical care units. Curr Pharm Biotechnol. 2011;12:2062–9.PubMedCrossRef
6.
Septimus EJ, Owens Jr RC. Need and potential of antimicrobial stewardship in community hospitals. Clin Infect Dis. 2011;53 Suppl 1:S8–S14.PubMedCrossRef
7.
Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control. 1995;23:87–94.
8.
Donskey CJ. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. Clin Infect Dis. 2006;43 Suppl 2:S62–9.PubMedCrossRef
9.
Salyers AA, Gupta A, Wang Y. Human intestinal bacteria as reservoirs for antibiotic resistance genes. Trends Microbiol. 2004;12:412–6.PubMedCrossRef
10.
11.
Bhalla A, Pultz NJ, Ray AJ, Hoyen CK, Eckstein EC, Donskey CJ. Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. Infect Control Hosp Epidemiol. 2003;24:644–9.PubMedCrossRef
12.
Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med. 2000;343:1925–32.PubMedPubMedCentralCrossRef
13.
Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55:905–14.PubMedPubMedCentralCrossRef
14.
Ruppé E, Lixandru B, Cojocaru R, Büke C, Paramythiotou E, Angebault C, et al. Relative fecal abundance of extended-spectrum-beta-lactamase-producing Escherichia coli strains and their occurrence in urinary tract infections in women. Antimicrob Agents Chemother. 2013;57:4512–7.PubMedPubMedCentralCrossRef
15.
Paphitou NI. Antimicrobial resistance: action to combat the rising microbial challenges. Int J Antimicrob Agents. 2013;42(Suppl):S25–8.PubMedCrossRef
16.
17.
Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology. 1981;81:5–9.PubMed
18.
Sartelli M, Malangoni MA, Abu-Zidan FM, Griffiths EA, Di Bella S, McFarland LV, et al. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg. 2015;10:38.PubMedPubMedCentralCrossRef
19.
Farrell RJ, LaMont JT. Pathogenesis and clinical manifestations of Clostridium difficile diarrhea and colitis. Curr Top Microbiol Immunol. 2000;250:109–25.PubMed
20.
Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67:742–8.PubMedCrossRef
21.
Muto CA, Pokrywka M, Shutt K, Mendelshon AB, Nouri K, Posey K, et al. A large outbreak of Clostridium difficile–associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26:273–80.PubMedCrossRef
22.
Loo VG, Poirier L, Miller MA, Oughton M, Libman MB, Michaud S, et al. A predominately clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442–9.PubMedCrossRef
23.
Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–60.PubMedCrossRef
24.
Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis. 2007;45:1543–9.PubMedCrossRef
25.
Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46:19–31.CrossRef
26.
McCusker ME, Harris AD, Perencevich E, Roghmann M. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis. 2003;9:730–3.PubMedPubMedCentralCrossRef
27.
Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;16(372):1539–48.CrossRef
28.
Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69:881–91.PubMedCrossRef
29.
Kim PK, Huh HC, Cohen HW, Feinberg EJ, Ahmad S, Coyle C, et al. Intracolonic vancomycin for severe Clostridium difficile colitis. Surg Infect (Larchmt). 2013;14:532–9.CrossRef
30.
Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostrodium difficile associated disease. Ann Surg. 2011;254:423–7.PubMedCrossRef
31.
Bougnoux ME, Diogo D, François N, Sendid B, Veirmeire S, Colombel JF, et al. Multilocus sequence typing reveals intrafamilial transmission and microevolutions of Candida albicans isolates from the human digestive tract. J Clin Microbiol. 2006;44:1810–20.PubMedPubMedCentralCrossRef
32.
Kam AP, Xu J. Diversity of commensal yeasts within and among healthy hosts. Diagn Microbiol Infect Dis. 2002;43:19–28.PubMedCrossRef
33.
Xu J, Boyd CM, Livingston E, Meyer W, Madden JF, Mitchell TG. Species and genotypic diversities and similarities of pathogenic yeasts colonizing women. J Clin Microbiol. 1999;37:3835–43.PubMedPubMedCentral
34.
Miranda LN, Van Der Heijden IM, Costa SF, Sousa AP, Sienra RA, Gobara S, et al. Candida colonisation as a source for candidaemia. J Hosp Infect. 2009;72:9–16.PubMedCrossRef
35.
Yan L, Yang C, Tang J. Disruption of the intestinal mucosal barrier in Candida albicans infections. Microbiol Res. 2013;168:389–95.PubMedCrossRef
36.
Schulte DM, Sethi A, Gangnon R, Duster M, Maki DG, Safdar N. Risk factors for Candida colonization and Co-colonization with multi-drug resistant organisms at admission. Antimicrob Resist Infect Control. 2015;4:46.PubMedPubMedCentralCrossRef
37.
Aly M, Balkhy HH. The prevalence of antimicrobial resistance in clinical isolates from gulf corporation council countries. Antimicrob Resist Infect Control. 2012;1:26.PubMedPubMedCentralCrossRef
38.
Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13:1057–98.PubMedCrossRef
39.
Ashiru-Oredope D, Cookson B, Fry C, Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection Professional Education Subgroup. Developing the first national antimicrobial prescribing and stewardship competences. J Antimicrob Chemother. 2014;69:2886–8.PubMedCrossRef
40.
Allegranzi B, Pittet D. Preventing infections acquired during health-care delivery. Lancet. 2008;372:1719–20.PubMedCrossRef
41.
42.
43.
Huttner A, Harbarth S, Carlet J, Cosgrove S, Goossens H, Holmes A, et al. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control. 2013;2:31.PubMedPubMedCentralCrossRef
44.
Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161–8.PubMedCrossRef
45.
Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–66.PubMedCrossRef
46.
Jacoby GA. Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams. Infect Dis Clin North Am. 1997;11:875–87.PubMedCrossRef
47.
Courpon-Claudinon A, Lefort A, Panhard X, Clermont O, Dornic Q, Fantin B, et al. Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features. Clin Microbiol Infect. 2011;17:557–65.PubMedCrossRef
48.
Thaden JT, Fowler VG, Sexton DJ, Anderson DJ. Increasing Incidence of Extended-Spectrum beta-lactamase-Producing Escherichia coli in Community Hospitals throughout the Southeastern United States. Infect Control Hosp Epidemiol. 2016;37:49–54.PubMedCrossRef
49.
Makoka MH, Miller WC, Hoffman IF, Cholera R, Gilligan PH, Kamwendo D, et al. Bacterial infections in Lilongwe, Malawi: aetiology and antibiotic resistance. BMC Infect Dis. 2012;12:67.PubMedPubMedCentralCrossRef
50.
McManus MC. Mechanisms of bacterial resistance to antimicrobial agents. Am J Health Syst Pharm. 1997;54:1420–33.PubMed
51.
52.
53.
Billard-Pomares T, Fouteau S, Jacquet ME, Roche D, Barbe V, Castellanos M, et al. Characterization of a P1-like bacteriophage carrying an SHV-2 extended-spectrum β-lactamase from an Escherichia coli strain. Antimicrob Agents Chemother. 2014;58(11):6550–7.PubMedPubMedCentralCrossRef
54.
Brown-Jaque M, Calero-Cáceres W, Muniesa M. Transfer of antibiotic-resistance genes via phage-related mobile elements. Plasmid. 2015;79:1–7.PubMedCrossRef
55.
Trueba G. Chapter Ten: The forces behind the dissemination of bacterial virulence and antibiotic resistance. In: Why does Evolution Matter? The Importance of Understanding Evolution. UK: Cambridge Scholars Publishing; 2014.
56.
Iida S, Meyer J, Arber W. Genesis and natural history of IS-mediated transposons. Cold Spring Harb Symp Quant Biol. 1981;45(Pt 1):27–43.PubMedCrossRef
57.
Poirel L, Marqué S, Héritier C, Segonds C, Chabanon G, Nordmann P. OXA-58, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother. 2005;49(1):202–8.PubMedPubMedCentralCrossRef
58.
Humeniuk C, Arlet G, Gautier V, Grimont P, Labia R, Philippon A. Beta-lactamases of Kluyvera ascorbata, probable progenitors of some plasmid-encoded CTX-M types. Antimicrob Agents Chemother. 2002;46(9):3045–9.PubMedPubMedCentralCrossRef
59.
Ray MD, Boundy S, Archer GL. Transfer of the methicillin resistance genomic island among staphylococci by conjugation. Mol Microbiol. 2016;100:675–85.PubMedPubMedCentralCrossRef
60.
61.
Smyth DS, McDougal LK, Gran FW, Manoharan A, Enright MC, Song JH, et al. Population structure of a hybrid clonal group of methicillin-resistant Staphylococcus aureus, ST239-MRSA-III. PLoS One. 2010;5(1), e8582.PubMedPubMedCentralCrossRef
62.
Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new beta-lactamases from Gram-negative bacteria. Annu Rev Microbiol. 2011;65:455–78.PubMedCrossRef
63.
Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980;289:321–31.PubMedCrossRef
64.
Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995;39:1211–33.PubMedPubMedCentralCrossRef
65.
Bush K, Jacoby GA. Updated Functional Classification of beta-Lactamases. Antimicrob Agents Chemother. 2010;54:969–76.PubMedCrossRef
66.
Ruppé É, Woerther PL, Barbier F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care. 2015;5:61.PubMedCrossRef
67.
68.
Kang CI, Pai H, Kim SH, Kim HB, Kim EC, Oh MD, et al. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediatedAmpC-type beta-lactamase. J Antimicrob Chemother. 2004;54:1130–3.PubMedCrossRef
69.
Tamma PD, Girdwood SC, Gopaul R, Tekle T, Roberts AA, Harris AD, et al. The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae. Clin Infect Dis. 2013;57:781–8.PubMedCrossRef
70.
Schultsz C, Geerlings S. Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy. Drugs. 2012;72:1–16.PubMedCrossRef
71.
72.
Brolund A. Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective. Infect Ecol Epidemiol. 2014;1:4.
73.
Perez F, Bonomo RA. Can we really use beta-lactam/beta-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum beta-lactamase-producing bacteria? Clin Infect Dis. 2012;54:175–7.PubMedCrossRef
74.
Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58:1072–83.PubMedCrossRef
75.
76.
Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum beta-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev. 2013;26:744–58.PubMedPubMedCentralCrossRef
77.
Weldhagen GF, Poirel L, Nordmann P. Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother. 2003;47:2385–92.PubMedPubMedCentralCrossRef
78.
79.
Hammoudi D, Ayoub Moubareck C, Aires J, Adaime A, Barakat A, Fayad N, et al. Countrywide spread of OXA-48 carbapenemase in Lebanon: surveillance and genetic characterization of carbapenem-non-susceptible Enterobacteriaceae in 10 hospitals over a one-year period. Int J Infect Dis. 2014;29:139–44.PubMedCrossRef
80.
Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004;48:15–22.PubMedPubMedCentralCrossRef
81.
Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG. Decreased susceptibility to polymyxin B during treatment of carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol. 2009;47:1611–2.PubMedPubMedCentralCrossRef
82.
Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45:1151–61.PubMedPubMedCentralCrossRef
83.
Ducomble T, Faucheux S, Helbig U, Kaisers UX, König B, Knaust A, et al. Large hospital outbreak of KPC-2-producing Klebsiella pneumoniae: investigating mortality and the impact of screening for KPC-2 with polymerase chain reaction. J Hosp Infect. 2015;89:179–85.PubMedCrossRef
84.
Lübbert C, Lippmann N, Busch T, Kaisers UX, Ducomble T, Eckmanns T, et al. Long-term carriage of Klebsiella pneumoniae carbapenemase-2-producing K pneumoniae after a large single-center outbreak in Germany. Am J Infect Control. 2014;42:376–80.PubMedCrossRef
85.
Lübbert C, Rodloff AC, Laudi S, Simon P, Busch T, Mössner J, et al. Lessons learned from excess mortality associated with Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in liver transplant recipients. Liver Transpl. 2014;20:736–8.PubMedCrossRef
86.
Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014;20:862–72.PubMedCrossRef
87.
Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785–96.PubMedPubMedCentralCrossRef
88.
89.
Cornaglia G, Giamarellou H, Rossolini GM. Metallo-beta-lactamases a last frontier for beta-lactams? Lancet Inf Dis. 2011;11:381–93.CrossRef
90.
Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53:5046–54.PubMedPubMedCentralCrossRef
91.
Brink AJ, Coetzee J, Clay CG, Sithole S, Richards GA, Poirel L, et al. Emergence of New Delhi Metallo-Beta-Lactamase (NDM-1) and Klebsiella pneumoniae Carbapenemase (KPC-2) in South Africa. J Clin Microbiol. 2012;50:525–7.PubMedPubMedCentralCrossRef
92.
Fàbrega A, Madurga S, Giralt E, Vila J. Mechanism of action of and resistance to quinolones. Microb Biotechnol. 2009;2:40–61.PubMedCrossRef
93.
94.
95.
Kumari H, Balasubramanian D, Zincke D, Mathee K. Role of Pseudomonas aeruginosa AmpR on beta-lactam and non-beta-lactam transient cross-resistance upon pre-exposure to subinhibitory concentrations of antibiotics. J Med Microbiol. 2014;63:544–55.PubMedPubMedCentralCrossRef
96.
Lister PD, Gardner VM, Sanders CC. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrob Agents Chemother. 1999;43:882–9.PubMedPubMedCentral
97.
Poole K. Efflux-mediated multiresistance in Gram-negative bacteria. Clin Microbiol Infect. 2004;10:12–26.PubMedCrossRef
98.
Venter H, Mowla R, Ohene-Agyei T, Ma S. RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition. Front Microbiol. 2015;6:377.PubMedPubMedCentralCrossRef
99.
Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM. Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol. 2012;302:63–8.PubMedCrossRef
100.
101.
Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents. 2015;45:568–85.PubMedCrossRef
102.
Linden PK. Optimizing therapy for vancomycin-resistant Enterococci (VRE). Semin Respir Crit Care Med. 2007;28:632–45.PubMedCrossRef
103.
Chou YY, Lin TY, Lin JC, Wang NC, Peng MY, Chang FY. Vancomycin-resistant enterococcal bacteremia: Comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis. J Microbiol Immunol Infect. 2008;41:124–9.PubMed
104.
105.
Hodges TL, Zighelboim-Daum S, Eliopoulos GM, Wennersten C, Moellering Jr RC. Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens. Antimicrob Agents Chemother. 1992;36:121–5.PubMedPubMedCentralCrossRef
106.
Marothi YA, Agnihotri H, Dubey D. Enterococcal resistance-an overview. Indian J Med Microbiol. 2005;23:214–9.PubMed
107.
Mahbub Alam M, Kobayashi N, Ishino M, Sumi A, Kobayashi K, Uehara N, et al. Detection of a novel aph(2″) allele (aph[2″]-Ie) conferring high-level gentamicin resistance and a spectinomycin resistance gene ant(9)-Ia (aad 9) in clinical isolates of enterococci. Microb Drug Resist. 2005;11:239–47.PubMedCrossRef
108.
Depardieu F, Podglajen I, Leclercq R, Collatz E, Courvalin P. Modes and modulations of antibiotic resistance gene expression. Clin Microbiol Rev. 2007;20:79–114.PubMedPubMedCentralCrossRef
109.
Noskin GA. Vancomycin-resistant Enterococci: Clinical, microbiologic, and epidemiologic features. J Lab Clin Med. 1997;130:14–20.PubMedCrossRef
110.
Fang H, Edlund C, Hedberg M, Nord CE. New findings in beta-lactam and metronidazole resistant Bacteroides fragilis group. Int J Antimicrob Agents. 2002;19:361–70.PubMedCrossRef
111.
Rasmussen BA, Bush K, Tally FP. Antimicrobial resistance in anaerobes. Clin Infect Dis. 1997;24 Suppl 1:S110–20.PubMedCrossRef
112.
Gutacker M, Valsangiacomo C, Piffaretti JC. Identification of two genetic groups in Bacteroides fragilis by multilocus enzyme electrophoresis: distribution of antibiotic resistance (cfiA, cepA) and enterotoxin (bft) encoding genes. Microbiology. 2000;146:1241–54.PubMedCrossRef
113.
Ang L, Brenwald NP, Walker RM, Andrews J, Fraise A. Carbapenem resistance in Bacteroides fragilis. J Antimicrob Chemother. 2007;59:1042–4.PubMedCrossRef
114.
Ingham HR, Eaton S, Venables CW, Adams PC. Bacteroides fragilis resistant to metronidazole after long-term therapy. Lancet. 1978;1:214.PubMedCrossRef
115.
Diniz CG, Farias LM, Carvalho MA, Rocha ER, Smith CJ. Differential gene expression in a Bacteroides fragilis metronidazole-resistant mutant. J Antimicrob Chemother. 2004;54:100–8.PubMedCrossRef
116.
Pumbwe L, Chang A, Smith RL, Wexler HM. BmeRABC5 is a multidrug efflux system that can confer metronidazole resistance in Bacteroides fragilis. Microb Drug Resist. 2007;13:96–101.PubMedCrossRef
117.
Nagy E, Urbán E, Nord CE, ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect. 2011;17:371–9.PubMedCrossRef
118.
Sartelli M, Catena F, Di Saverio S, Ansaloni L, Coccolini F, Tranà C, et al. The Challenge of antimicrobial resistance in managing intra-abdominal infections. Surg Infect (Larchmt). 2015;16:213–20.CrossRef
119.
Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. A review of ten years of the study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel). 2013;6:1335–46.CrossRef
120.
Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Cantón R, Baquero F. Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2010;54:3043–6.PubMedPubMedCentralCrossRef
121.
Sartelli M, Catena F, Ansaloni L, Coccolini F, Corbella D, Moore EE, et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. World J Emerg Surg. 2014;9:37.PubMedPubMedCentralCrossRef
122.
Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, Badal RE, et al. Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates. Antimicrob Agents Chemother. 2011;55:3917–21.PubMedPubMedCentralCrossRef
123.
Babinchak T, Badal R, Hoban D, Hackel M, Hawser S, Lob S, et al. Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005–2010. Diagn Microbiol Infect Dis. 2013;76:379–81.PubMedCrossRef
124.
Sitges-Serra A, Lopez MJ, Girvent M, Almirall S, Sancho JJ. Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg. 2002;89:361–7.PubMedCrossRef
125.
Burnett RJ, Haverstock DC, Dellinger EP, Reinhart HH, Bohnen JM, Rotstein OD, et al. Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery. 1995;118:716–21.PubMedCrossRef
126.
Dupont H, Friggeri A, Touzeau J, Airapetian N, Tinturier F, Lobjoie E, et al. Enterococci increase the morbidity and mortality associated with severe intra-abdominal infections in elderly patients hospitalized in the intensive care unit. J Antimicrob Chemother. 2011;66:2379–85.PubMedCrossRef
127.
Kaffarnik MF, Urban M, Hopt UT, Utzolino S. Impact of enterococcus on immunocompetent and immunosuppressed patients with perforation of the small or large bowel. Technol Health Care. 2012;20:37–48.PubMed
128.
Van Ruler O, Kiewiet JJ, Van Ketel RJ, Boermeester MA, Dutch Peritonitis Study Group. Initial microbial spectrum in severe secondary peritonitis and relevance for treatment. Eur J Clin Microbiol Infect Dis. 2012;31:671–82.PubMedCrossRef
129.
Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother. 2009;63:785–94.PubMedCrossRef
130.
Verma H, Pandey S, Sheoran KD, Marwah S. Surgical audit of patients with ileal perforations requiring ileostomy in a Tertiary Care Hospital in India. Surg Res Pract. 2015;2015:351548.PubMedPubMedCentral
131.
Mirza SH, Beeching NJ, Hart CA. Multi-drug resistant typhoid: a global problem. J Med Microbiol. 1996;44:317–9.PubMedCrossRef
132.
Hammad OM, Abdel Wahab MF, Zaky S, Abdel Baki AM, Afify A, El Tantawi MA. Multidrug resistant typhoid fever in Egypt. J Med Lab Sci. 2007;16:57–63.
133.
Singhal L, Gupta PK, Kale P, Gautam V, Ray P. Trends in antimicrobial susceptibility of Salmonella typhi from North India (2001–2012). Indian J Med Microbiol. 2014;32:149–52.PubMedCrossRef
134.
135.
Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJ, et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005–2007). Clin Infect Dis. 2010;50 Suppl 1:S26–33.PubMedCrossRef
136.
Ramsay C, Brown E, Hartman G, Davey P. Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing. J Antimicrob Chemother. 2003;52:764–71.PubMedCrossRef
137.
Dortch MJ, Fleming SB, Kauffmann RM, Dossett LA, Talbot TR, May AK. Infection reduction strategies including antibiotic stewardship protocols in surgical and trauma intensive care units are associated with reduced resistant gram-negative healthcare-associated infections. Surg Infect (Larchmt). 2011;12:15–25.CrossRef
138.
White Jr AC, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997;25:230–9.PubMedCrossRef
139.
Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2013;4, CD003543.
140.
Marshall JC. Principles of source control in the early management of sepsis. Curr Infect Dis Rep. 2010;12:345–53.PubMedCrossRef
141.
Wacha H, Hau T, Dittmer R, Ohmann C. Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg. 1999;384:24–32.PubMedCrossRef
142.
Sartelli M, Abu-Zidan FM, Catena F, Griffiths EA, Di Saverio S, Coimbra R, et al. Global validation of the WSES Sepsis Severity Score for patients with complicated intra-abdominal infections: a prospective multicentre study (WISS Study). World J Emerg Surg. 2015;10:61.PubMedPubMedCentralCrossRef
143.
VanSonnenberg E, Ferrucci JT, Mueller PR, Wittenberg J, Simeone JF. Percutaneous drainage of abscesses and fluid collections: Technique, results, and applications. Radiology. 1982;142:1–10.PubMedCrossRef
144.
Bouali K, Magotteaux P, Jadot A, Saive C, Lombard R, Weerts J, et al. Percutaneous catheter drainage of abdominal abscess after abdominal surgery: Results in 121 cases. J Belg Radiol. 1993;76:11–4.PubMed
145.
VanSonnenberg E, Wing VW, Casola G, Coons HG, Nakamoto SK, Mueller PR, et al. Temporizing effect of percutaneous drainage of complicated abscesses in critically ill patients. Am J Roentgenol. 1984;142:821–6.CrossRef
146.
Jaffe TA, Nelson RC, DeLong D, Paulson EK. Practice Patterns in Percutaneous Image-guided Intra-abdominal Abscess Drainage: Survey of Academic and Private Practice Centres. Radiology. 2004;233:750–6.PubMedCrossRef
147.
Kirkpatrick AW, Roberts DJ, De Waele J, Jaeschke R, Malbrain ML, De Keulenaer B, et al. Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. Intensive Care Med. 2013;39:1190–206.PubMedPubMedCentralCrossRef
148.
Kirkpatrick AW, Roberts DJ, Faris PD, Ball CG, Kubes P, Tiruta C, et al. Active Negative Pressure Peritoneal Therapy After Abbreviated Laparotomy: The Intraperitoneal Vacuum Randomized Controlled Trial. Ann Surg. 2015;262:38–46.PubMedPubMedCentralCrossRef
149.
Menichetti F, Sganga G. Definition and classification of intra-abdominal infections. J Chemother. 2009;21 Suppl 1:3–4.PubMedCrossRef
150.
151.
152.
153.
Reemst PH, Van Goor H, Goris RJ. SIRS, MODS and tertiary peritonitis. Eur J Surg Suppl. 1996;576:47–8. discussion 49.
154.
Chromik AM, Meiser A, Hölling J, Sülberg D, Daigeler A, Meurer K, et al. Identification of patients at risk for development of tertiary peritonitis on a surgical intensive care unit. J Gastrointest Surg. 2009;13:1358–67.PubMedCrossRef
155.
Herzog T, Chromik AM, Uhl W. Treatment of complicated intra-abdominal infections in the era of multi-drug resistant bacteria. Eur J Med Res. 2010;15:525–32.PubMedPubMedCentralCrossRef
156.
Roehrborn A, Thomas L, Potreck O, Ebener C, Ohmann C, Goretzki PE, et al. The microbiology of postoperative peritonitis. Clin Infect Dis. 2001;33:1513–9.PubMedCrossRef
157.
Mulier S, Penninckx F, Verwaest C, Filez L, Aerts R, Fieuws S, et al. Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients. World J Surg. 2003;27:379–84.PubMedCrossRef
158.
159.
Seguin P, Fédun Y, Laviolle B, Nesseler N, Donnio PY, Mallédant Y. Risk factors for multidrug-resistant bacteria in patients with post-operative peritonitis requiring intensive care. J Antimicrob Chemother. 2010;65:342–6.PubMedCrossRef
160.
Augustin P, Kermarrec N, Muller-Serieys C, Lasocki S, Chosidow D, Marmuse JP, et al. Risk factors for multi drug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care. 2010;14(1):R20.PubMedPubMedCentralCrossRef
161.
Montravers P, Chalfine A, Gauzit R, Lepape A, Pierre Marmuse J, Vouillot C, et al. Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections. Ann Surg. 2004;239:409–16.PubMedPubMedCentralCrossRef
162.
Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137:791–7.PubMedCrossRef
163.
Cardoso T, Almeida M, Friedman ND, Aragão I, Costa-Pereira A, Sarmento E, et al. Classification of healthcare-associated infection: a systematic review 10 years after the first proposal. BMC Med. 2014;12:40.PubMedPubMedCentralCrossRef
164.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidlines for the use of innovative therapies in sepsis. Chest. 1992;101:1644–55.PubMedCrossRef
165.
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250–6.PubMedCrossRef
166.
Esteban A, Frutos-Vivar F, Ferguson ND, Peñuelas O, Lorente JA, Gordo F, et al. Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Crit Care Med. 2007;35:1284–9.PubMedCrossRef
167.
Sartelli M, Catena F, Di Saverio S, Ansaloni L, Malangoni M, Moore EE, et al. Current concept of abdominal sepsis: WSES position paper. World J Emerg Surg. 2014;9:22.PubMedPubMedCentralCrossRef
168.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801–10.PubMedPubMedCentralCrossRef
169.
Cain SE, Kohn J, Bookstaver PB, Albrecht H, Al-Hasan MN. Stratification of the impact of inappropriate empirical antimicrobial therapy for Gram-negative bloodstream infections by predicted prognosis. Antimicrob Agents Chemother. 2015;59:245–50.PubMedCrossRef
170.
Guirao X, Arias J, Badía JM, García-Rodríguez JA, Mensa J, Alvarez-Lerma F, et al. Recommendations in the empiric anti-infective agents of intra-abdominal infection. Rev Esp Quimioter. 2009;22:151–72.PubMed
171.
Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt). 2010;11:79–109.CrossRef
172.
Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis. 2003;37:997–1005.PubMedCrossRef
173.
Mazuski JE, Sawyer RG, Nathens AB, DiPiro JT, Schein M, Kudsk KA, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect (Larchmt). 2002;3:161–73.CrossRef
174.
Sartelli M, Viale P, Catena F, Ansaloni L, Moore E, Malangoni M, et al. 2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2013;8:3.PubMedPubMedCentralCrossRef
175.
Sartelli M, Viale P, Koike K, Pea F, Tumietto F, Van Goor H, et al. WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. World J Emerg Surg. 2011;6:2.PubMedPubMedCentralCrossRef
176.
Chow AW, Evans GA, Nathens AB, Ball CG, Hansen G, Harding GK, et al. Canadian practice guidelines for surgical intra-abdominal infections. Can J Infect Dis Med Microbiol. 2010;21:11–37.PubMedPubMedCentral
177.
Gomi H, Solomkin JS, Takada T, Strasberg SM, Pitt HA, Yoshida M, et al. TG13 antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013;20:60–70.PubMedCrossRef
178.
Montravers P, Dupont H, Leone M, Constantin JM, Mertes PM, Société française d’anesthésie et de réanimation (Sfar), et al. Guidelines for management of intra-abdominal infections. Anaesth Crit Care Pain Med. 2015;34:117–30.PubMedCrossRef
179.
Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a five-fold reduction of survival in human septic shock. Chest. 2009;136:1237–48.PubMedCrossRef
180.
Tumbarello M, Trecarichi EM, Bassetti M, De Rosa FG, Spanu T, Di Meco E, et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother. 2011;55:3485–90.PubMedPubMedCentralCrossRef
181.
Al-Hasan MN, Eckel-Passow JE, Baddour LM. Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study. Eur J Clin Microbiol Infect Dis. 2012;31:1163–71.PubMedCrossRef
182.
Ruppé E, Armand-Lefèvre L, Estellat C, Consigny PH, El Mniai A, Boussadia Y, et al. High Rate of Acquisition but Short Duration of Carriage of Multidrug-Resistant Enterobacteriaceae After ravel to the Tropics. Clin Infect Dis. 2015;61:593–600.PubMedCrossRef
183.
McDonald LC. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin Infect Dis. 2006;42 Suppl 2:S65–71.PubMedCrossRef
184.
Montravers P, Augustin P, Grall N, Desmard M, Allou N, Marmuse JP, Guglielminotti J. Characteristics and outcomes of anti-infective de-escalation during health care-associated intra-abdominal infections. Crit Care. 2016;20(1):83.PubMedPubMedCentralCrossRef
185.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10.PubMedCrossRef
186.
Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–9.PubMedCrossRef
187.
De Waele J, Lipman J, Sakr Y, Marshall JC, Vanhems P, Barrera Groba C, et al. Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome. BMC Infect Dis. 2014;14:420.PubMedPubMedCentralCrossRef
188.
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–96.PubMedCrossRef
189.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165–228.PubMedCrossRef
190.
Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother. 2010;54:4851–63.PubMedPubMedCentralCrossRef
191.
Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, et al. Edusepsis Study Group: Effectiveness of treatments for severe sepsis: A prospective, multicenter, observational study. Am J Respir Crit Care Med. 2009;180:861–6.PubMedCrossRef
192.
Castellanos-Ortega A, Suberviola B, García-Astudillo LA, Holanda MS, Ortiz F, Llorca J, et al. Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: Results of a three-year follow-up quasi-experimental study. Crit Care Med. 2010;38:1036–43.PubMedCrossRef
193.
Puskarich MA, Trzeciak S, Shapiro NI, Arnold RC, Horton JM, Studnek JR, et al. Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med. 2011;39:2066–71.PubMedPubMedCentralCrossRef
194.
Rello J, Vidaur L, Sandiumenge A, Rodriguez A, Gualis B, Boque C, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med. 2004;32:2183–90.PubMedCrossRef
195.
Alvarez-Lerma F, Alvarez B, Luque P, Ruiz F, Dominguez-Roldan JM, Quintana E, et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care. 2006;10:R78.PubMedPubMedCentralCrossRef
196.
Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma. 2009;66:1343–8.PubMedCrossRef
197.
Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernández-Delgado E, Herrera-Melero I, et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med. 2014;40:32–40.PubMedCrossRef
198.
Leone M, Bechis C, Baumstarck K, Lefrant JY, Albanèse J, Jaber S, et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med. 2014;40:1399–408.PubMedCrossRef
199.
Silva BN, Andriolo RB, Atallah AN, Salomão R. De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev. 2013;3, CD007934.
200.
Madaras-Kelly K, Jones M, Remington R, Caplinger C, Huttner B, Samore M. Description and validation of a spectrum score method to measure antimicrobial de-escalation in healthcare associated pneumonia from electronic medical records data. BMC Infect Dis. 2015;15:197.PubMedPubMedCentralCrossRef
201.
Cisneros JM, Neth O, Gil-Navarro MV, Lepe JA, Jiménez-Parrilla F, Cordero E, et al. Global impact of an educational antimicrobial stewardship programme on prescribing practice in a tertiary hospital centre. Clin Microbiol Infect. 2014;20:82–8.PubMedCrossRef
202.
Lew KY, Ng TM, Tan M, Tan SH, Lew EL, Ling LM, et al. Safety and clinical outcomes of carbapenem de-escalation as part of anantimicrobial stewardship programme in an ESBL-endemic setting. J Antimicrob Chemother. 2015;70:1219–25.PubMed
203.
Tucker CE, Lockwood AM, Nguyen NH. Antibiotic dosing in obesity: the search for optimum dosing strategies. Clin Obes. 2014;4:287–95.PubMed
204.
Hackel MA, Badal RE, Bouchillon SK, Biedenbach DJ, Hoban DJ. Resistance rates of intra-abdominal isolates from intensive care units and non-intensive care units in the United States: the study for monitoring antimicrobial resistance trends 2010–2012. Surg Infect (Larchmt). 2015;16:298–304.CrossRef
205.
Powell LL, Wilson SE. The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection. Surg Infect (Larchmt). 2000;1:57–63.CrossRef
206.
Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998–2007. J Antimicrob Chemother. 2009;64:169–74.PubMedPubMedCentralCrossRef
207.
Johnson JR, Owens K, Gajewski A, Clabots C. Escherichia coli colonization patterns among human household members and pets, with attention to acute urinary tract infection. J Infect Dis. 2008;197:218–24.PubMedCrossRef
208.
Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 2007;5:365–83.PubMedCrossRef
209.
Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:2793–803.PubMedCrossRef
210.
Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis. 2015;60:1319–25.PubMedPubMedCentral
211.
Harris PN, Tambyah PA, Paterson DL. Beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015;15:475–85.PubMedCrossRef
212.
Garbino J, Villiger P, Caviezel A, Matulionyte R, Uckay I, Morel P, et al. A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections. Infection. 2007;35:161–6.PubMedCrossRef
213.
Henry X, Amoroso A, Coyette J, Joris B. Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium. Antimicrob Agents Chemother. 2010;54:953–5.PubMedCrossRef
214.
Liapikou A, Cillóniz C, Torres A. Ceftobiprole for the treatment of pneumonia: a European perspective. Drug Design, Development and Therapy. 2015;9:4565–72.PubMedPubMedCentral
215.
Queenan AM, Shang W, Kania M, Page MG, Bush K. Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrob Agents Chemother. 2007;51:3089–95.PubMedPubMedCentralCrossRef
216.
Falagas ME, Matthaiou DK, Bliziotis IA. Systematic review: Fluoroquinolones for the treatment of intra-abdominal surgical infections. Aliment Pharmacol Ther. 2007;25:123–31.PubMedCrossRef
217.
Borcherding SM, Stevens R, Nicholas RA, Corley CR, Self T. Quinolones: A practical review of clinical uses, dosing considerations, and drug interactions. J Fam Pract. 1996;42:69–78.PubMed
218.
Ortega M, Marco F, Soriano A, Almela M, Martínez JA, Muñoz A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother. 2009;63:568–74.PubMedCrossRef
219.
Banerjee R, Johnston B, Lohse C, Porter SB, Clabots C, Johnson JR. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol. 2013;34:361–9.PubMedPubMedCentralCrossRef
220.
Patterson JE. Antibiotic utilization: is there an effect on antimicrobial resistance? Chest. 2001;119(2 Suppl):426S–30S.PubMedCrossRef
221.
Sartelli M, Catena F, Coccolini F, Pinna AD. Antimicrobial management of intra-abdominal infections: literature's guidelines. World J Gastroenterol. 2012;18:865–71.PubMedPubMedCentralCrossRef
222.
Falagas ME, Peppas G, Makris GC, Karageorgopoulos DE, Matthaiou DK. Meta-analysis: Ertapenem for complicated intra-abdominal infections. Aliment Pharmacol Ther. 2008;27:919–31.PubMedCrossRef
223.
Lepper PM, Grusa E, Reichl H, Högel J, Trautmann M. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2002;46:2920–5.PubMedPubMedCentralCrossRef
224.
Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322–8.PubMedPubMedCentralCrossRef
225.
Trivedi M, Patel V, Soman R, Rodriguez C, Singhal T. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials. J Assoc Physicians India. 2012;60:28–30.PubMed
226.
Dupont H, Carbon C, Carlet J. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group. Antimicrob Agents Chemother. 2000;44:2028–33.PubMedPubMedCentralCrossRef
227.
Heizmann WR, Löschmann PA, Eckmann C, Von Eiff C, Bodmann KF, Petrik C. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria. Infection. 2015;43:37–43.PubMedCrossRef
228.
McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents. 2013;41:463–7.PubMedCrossRef
229.
Bassetti M, McGovern PC, Wenisch C, Meyer RD, Yan JL, Wible M, et al. Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials. Int J Antimicrob Agents. 2015;46:346–50.PubMedCrossRef
230.
Montravers P, Dupont H, Bedos JP, Bret P. Tigecycline Group. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting. Intensive Care Med. 2014;40:988–97.PubMedPubMedCentralCrossRef
231.
Eckmann C, Montravers P, Bassetti M, Bodmann KF, Heizmann WR, Sánchez García M, et al. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother. 2013;68 Suppl 2:ii25–35.PubMed
232.
Chen YH, Hsueh PR. Changing bacteriology of abdominal and surgical sepsis. Curr Opin Infect Dis. 2012;25:590–5.PubMedCrossRef
233.
Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682–707.PubMedPubMedCentralCrossRef
234.
De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18:R90.PubMedPubMedCentralCrossRef
235.
Falagas ME, Rafailidis PI. Re-emergence of colistin in today’s world of multidrug-resistant organisms: personal perspectives. Expert Opin Investig Drugs. 2008;17:973–81.PubMedCrossRef
236.
Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 2006;25:596–9.PubMedCrossRef
237.
Ruiz J, Núñez ML, Pérez J, Simarro E, Martínez-Campos L, Gómez J. Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period. Eur J Clin Microbiol Infect Dis. 1999;18:292–5.PubMedCrossRef
238.
Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-WittelI M, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36:1111–8.PubMedCrossRef
239.
Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53(8):3430–6.PubMedPubMedCentralCrossRef
240.
Nation RL, Garonzik SM, Li J, Thamlikitkul V, Giamarellos-Bourboulis EJ, Paterson DL, et al. Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform? Clin Infect Dis. 2016;62:552–8.PubMedCrossRef
241.
Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43(1):52–9.PubMedCrossRef
242.
Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15:e732–9.PubMedCrossRef
243.
Reffert JL, Smith WJ. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2014;34:845–57.PubMedCrossRef
244.
Eckmann C, Solomkin J. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections. Expert Opin Pharmacother. 2015;16:271–80.PubMedCrossRef
245.
Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, et al. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462–71.PubMedPubMedCentralCrossRef
246.
Mawal Y, Critchley IA, Riccobene TA, Talley AK. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-bdominal infections. Expert Rev Clin Pharmacol. 2015;8:691–707.PubMedCrossRef
247.
Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection–results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016 [Epub ahead of print]
248.
Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and Ceftazidime/avibactam: two novel beta-lactam/beta-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015;46:266–71.PubMedCrossRef
249.
Holden MT, Hsu LY, Kurt K, Weinert LA, Mather AE, Harris SR, et al. A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic. Genome Res. 2013;23:653–64.PubMedPubMedCentralCrossRef
250.
Skalweit MJ. Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections. Drug Des Devel Ther. 2015;9:2919–25.PubMedPubMedCentralCrossRef
251.
Montravers P, Dupont H, Gauzit R, Veber B, Auboyer C, Blin P, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med. 2006;34:646–52.PubMedCrossRef
252.
Zappella N, Desmard M, Chochillon C, Ribeiro-Parenti L, Houze S, Marmuse JP, et al. Positive peritoneal fluid fungal cultures in postoperative peritonitis after bariatric surgery. Clin Microbiol Infect. 2015;21:853.e1-3.PubMedCrossRef
253.
Montravers P, Mira JP, Gangneux JP, Leroy O, Lortholary O. AmarCand study group. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect. 2011;17:1061–7.PubMedCrossRef
254.
Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.PubMedCrossRef
255.
Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother. 2006;57:628–38.PubMedCrossRef
256.
Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med. 2005;33:1928–35.PubMedCrossRef
257.
Vardakas KZ, Samonis G, Michalopoulos A, Soteriades ES, Falagas ME. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med. 2006;34:1216–24.PubMedCrossRef
258.
Cruciani M, De Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med. 2005;31:1479–87.PubMedCrossRef
259.
Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18 Suppl 7:19–37.PubMedCrossRef
260.
Knitsch W, Vincent JL, Utzolino S, François B, Dinya T, Dimopoulos G, et al. A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections. Clin Infect Dis. 2015;61(11):1671–8.PubMedPubMedCentral
261.
Allou N, Allyn J, Montravers P. When and how to cover for fungal infections in patients with severe sepsis and septic shock. Curr Infect Dis Rep. 2011;13:426–32.PubMedCrossRef
262.
Shields RK, Nguyen MH, Press EG, Clancy CJ. Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrob Agents Chemother. 2014;58:7601–5.PubMedPubMedCentralCrossRef
263.
Müller M, Dela Peña A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother. 2004;48:1441–53.PubMedPubMedCentralCrossRef
264.
Gonzalez D, Schmidt S, Derendorf H. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev. 2013;26:274–88.PubMedPubMedCentralCrossRef
265.
Seguin P, Verdier MC, Chanavaz C, Engrand C, Laviolle B, Donnio PY, et al. Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis. J Antimicrob Chemother. 2009;63:564–7.PubMedCrossRef
266.
Buijk SL, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother. 2002;49:121–8.PubMedCrossRef
267.
Dahyot-Fizelier C, Lefeuvre S, Laksiri L, Marchand S, Sawchuk RJ, Couet W, et al. Kinetics of imipenem distribution into the peritoneal fluid of patients with severe peritonitis studied by microdialysis. Clin Pharmacokinet. 2010;49:323–34.PubMedCrossRef
268.
Karjagin J, Lefeuvre S, Oselin K, Kipper K, Marchand S, Tikkerberi A, et al. Pharmacokinetics of meropenem determined by icrodialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther. 2008;83:452–9.PubMedCrossRef
269.
270.
Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509.PubMedPubMedCentralCrossRef
271.
272.
Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock-does the dose matter? Crit Care. 2009;13:214.PubMedPubMedCentralCrossRef
273.
Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2006;50:3556–61.PubMedPubMedCentralCrossRef
274.
Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, et al. A Multicenter Randomized Trial of Continuous versus Intermittent beta-lactam Infusion in Severe Sepsis. Am J Respir Crit Care Med. 2015;192:1298–305.PubMedCrossRef
275.
Lodise Jr TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44:357–63.PubMedCrossRef
276.
Lorente L, Jiménez A, Martín MM, Iribarren JL, Jiménez JJ, Mora ML. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents. 2009;33:464–8.PubMedCrossRef
277.
Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 1996;124:717–25.PubMedCrossRef
278.
Udy AA, Baptista JP, Lim NL, Joynt GM, Jarrett P, Wockner L, et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Crit Care Med. 2014;42:520–7.PubMedCrossRef
279.
Gladman MA, Knowles CH, Gladman LJ, Payne JG. Intra-operative culture in appendicitis: traditional practice challenged. Ann R Coll Surg Engl. 2004;86:196–201.PubMedPubMedCentralCrossRef
280.
Davies HO, Alkhamesi NA, Dawson PM. Peritoneal fluid culture in appendicitis: review in changing times. Int J Surg. 2010;8:426–9.PubMedCrossRef
281.
Marchese A, Esposito S, Barbieri R, Bassetti M, Debbia E. Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections? BMC Infect Dis. 2012;12:181.PubMedPubMedCentralCrossRef
282.
Wolfensberger A, Sax H, Weber R, Zbinden R, Kuster SP, Hombach M. Change of antibiotic susceptibility testing guidelines from CLSI to EUCAST: influence on cumulative hospital antibiograms. PLoS One. 2013;8, e79130.PubMedPubMedCentralCrossRef
283.
Van der Bij AK, Van Dijk K, Muilwijk J, Thijsen SF, Notermans DW, De Greeff S, et al. Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia. Clin Microbiol Infect. 2012;18:E466–72.PubMedCrossRef
284.
Polsfuss S, Bloemberg GV, Giger J, Meyer V, Hombach M. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum beta-lactamase production in clinical Enterobacteriaceae isolates. J Antimicrob Chemother. 2012;67:159–66.PubMedCrossRef
285.
Hombach M, Mouttet B, Bloemberg GV. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC beta-lactamase-producing clinical Enterobacteriaceae isolates. J Antimicrob Chemother. 2013;68:2092–8.PubMedCrossRef
286.
Andersen BR, Kallehave FL, Andersen HK. Antibiotics versus placebo for prevention of postoperative infection after appendicectomy. Cochrane Database Syst Rev. 2005;3, CD001439.
287.
Mazeh H, Mizrahi I, Dior U, Simanovsky N, Shapiro M, Freund HR, et al. Role of antibiotic therapy in mild acute calculus cholecystitis: a prospective andomized controlled trial. World J Surg. 2012;36:1750–9.PubMedCrossRef
288.
Regimbeau JM, Fuks D, Pautrat K, Mauvais F, Haccart V, Msika S, et al. Effect of postoperative antibiotic administration on postoperative infection following cholecystectomy for acute calculous cholecystitis: a randomized clinical trial. JAMA. 2014;312:145–54.PubMedCrossRef
289.
Bhangu A, Søreide K, Di Saverio S, Assarsson JH, Drake FT. Acute appendicitis: modern understanding of pathogenesis, diagnosis, and management. Lancet. 2015;386:1278–87.PubMedCrossRef
290.
291.
Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372:1996–2005.PubMedPubMedCentralCrossRef
292.
Riccio LM, Popovsky KA, Hranjec T, Politano AD, Rosenberger LH, Tura KC, et al. Association of excessive duration of antibiotic therapy for intra-abdominal infection with subsequent extra-abdominal infection and death: a study of 2,552 consecutive infections. Surg Infect (Larchmt). 2014;15:417–24.CrossRef
293.
Hochreiter M, Köhler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care. 2009;13:R83.PubMedPubMedCentralCrossRef
294.
Xiao Z, Wilson C, Robertson HL, Roberts DJ, Ball CG, Jenne CN, et al. Inflammatory mediators in intra-abdominal sepsis or injury–a scoping review. Crit Care. 2015;19:373.PubMedPubMedCentralCrossRef
295.
Tschaikowsky K, Hedwig-Geissing M, Braun GG, Radespiel-Troeger M. Predictive value of procalcitonin, interleukin-6, and C-reactive protein for survival in postoperative patients with severe sepsis. J Crit Care. 2011;26:54–64.PubMedCrossRef
296.
Azevedo JR, Torres OJ, Czeczko NG, Tuon FF, Nassif PA, Souza GD. Procalcitonin as a prognostic biomarker of severe sepsis and septic shock. Rev Col Bras Cir. 2012;39:456–61.PubMedCrossRef
297.
Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg. 2009;394:221–6.PubMedCrossRef
298.
Jung B, Molinari N, Nasri M, Hajjej Z, Chanques G, Jean-Pierre H, et al. Procalcitonin biomarker kinetics fails to predict treatment response in perioperative abdominal infection with septic shock. Crit Care. 2013;17:R255.PubMedPubMedCentralCrossRef
299.
Centers for Disease Control and Prevention (CDC). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. Morb Mortal Wkly Rep. 2009;58:256–60.
Metadata
Title
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)
Authors
Massimo Sartelli
Dieter G. Weber
Etienne Ruppé
Matteo Bassetti
Brian J. Wright
Luca Ansaloni
Fausto Catena
Federico Coccolini
Fikri M. Abu-Zidan
Raul Coimbra
Ernest E. Moore
Frederick A. Moore
Ronald V. Maier
Jan J. De Waele
Andrew W. Kirkpatrick
Ewen A. Griffiths
Christian Eckmann
Adrian J. Brink
John E. Mazuski
Addison K. May
Rob G. Sawyer
Dominik Mertz
Philippe Montravers
Anand Kumar
Jason A. Roberts
Jean-Louis Vincent
Richard R. Watkins
Warren Lowman
Brad Spellberg
Iain J. Abbott
Abdulrashid Kayode Adesunkanmi
Sara Al-Dahir
Majdi N. Al-Hasan
Ferdinando Agresta
Asma A. Althani
Shamshul Ansari
Rashid Ansumana
Goran Augustin
Miklosh Bala
Zsolt J. Balogh
Oussama Baraket
Aneel Bhangu
Marcelo A. Beltrán
Michael Bernhard
Walter L. Biffl
Marja A. Boermeester
Stephen M. Brecher
Jill R. Cherry-Bukowiec
Otmar R. Buyne
Miguel A. Cainzos
Kelly A. Cairns
Adrian Camacho-Ortiz
Sujith J. Chandy
Asri Che Jusoh
Alain Chichom-Mefire
Caroline Colijn
Francesco Corcione
Yunfeng Cui
Daniel Curcio
Samir Delibegovic
Zaza Demetrashvili
Belinda De Simone
Sameer Dhingra
José J. Diaz
Isidoro Di Carlo
Angel Dillip
Salomone Di Saverio
Michael P. Doyle
Gereltuya Dorj
Agron Dogjani
Hervé Dupont
Soumitra R. Eachempati
Mushira Abdulaziz Enani
Valery N. Egiev
Mutasim M. Elmangory
Paula Ferrada
Joseph R. Fitchett
Gustavo P. Fraga
Nathalie Guessennd
Helen Giamarellou
Wagih Ghnnam
George Gkiokas
Staphanie R. Goldberg
Carlos Augusto Gomes
Harumi Gomi
Manuel Guzmán-Blanco
Mainul Haque
Sonja Hansen
Andreas Hecker
Wolfgang R. Heizmann
Torsten Herzog
Adrien Montcho Hodonou
Suk-Kyung Hong
Reinhold Kafka-Ritsch
Lewis J. Kaplan
Garima Kapoor
Aleksandar Karamarkovic
Martin G. Kees
Jakub Kenig
Ronald Kiguba
Peter K. Kim
Yoram Kluger
Vladimir Khokha
Kaoru Koike
Kenneth Y. Y. Kok
Victory Kong
Matthew C. Knox
Kenji Inaba
Arda Isik
Katia Iskandar
Rao R. Ivatury
Maurizio Labbate
Francesco M. Labricciosa
Pierre-François Laterre
Rifat Latifi
Jae Gil Lee
Young Ran Lee
Marc Leone
Ari Leppaniemi
Yousheng Li
Stephen Y. Liang
Tonny Loho
Marc Maegele
Sydney Malama
Hany E. Marei
Ignacio Martin-Loeches
Sanjay Marwah
Amos Massele
Michael McFarlane
Renato Bessa Melo
Ionut Negoi
David P. Nicolau
Carl Erik Nord
Richard Ofori-Asenso
AbdelKarim H. Omari
Carlos A. Ordonez
Mouaqit Ouadii
Gerson Alves Pereira Júnior
Diego Piazza
Guntars Pupelis
Timothy Miles Rawson
Miran Rems
Sandro Rizoli
Claudio Rocha
Boris Sakakhushev
Miguel Sanchez-Garcia
Norio Sato
Helmut A. Segovia Lohse
Gabriele Sganga
Boonying Siribumrungwong
Vishal G. Shelat
Kjetil Soreide
Rodolfo Soto
Peep Talving
Jonathan V. Tilsed
Jean-Francois Timsit
Gabriel Trueba
Ngo Tat Trung
Jan Ulrych
Harry van Goor
Andras Vereczkei
Ravinder S. Vohra
Imtiaz Wani
Waldemar Uhl
Yonghong Xiao
Kuo-Ching Yuan
Sanoop K. Zachariah
Jean-Ralph Zahar
Tanya L. Zakrison
Antonio Corcione
Rita M. Melotti
Claudio Viscoli
Perluigi Viale
Publication date
01-12-2016
Publisher
BioMed Central
Published in
World Journal of Emergency Surgery / Issue 1/2016
Electronic ISSN: 1749-7922
DOI
https://doi.org/10.1186/s13017-016-0089-y

Other articles of this Issue 1/2016

World Journal of Emergency Surgery 1/2016 Go to the issue

Research article

Wells criteria for DVT is a reliable clinical tool to assess the risk of deep venous thrombosis in trauma patients

Research article

Validity of predictive factors of acute complicated appendicitis

Research article

Review of 58 patients with necrotizing fasciitis in the Netherlands

Erratum

Erratum to: Poor prognostic factors in patients who underwent surgery for acute non-occlusive ischemic colitis

Review

How to improve the clinical diagnosis of acute appendicitis in resource limited settings

Research article

Emergency General Surgery: evolution of a subspecialty by stealth